The study identified several characteristics to observe in HIV patients who develop broadly neutralizing HIV antibodies (bnAbs), which occur naturally in about one percent of those infected with the disease and could be key in an eventual vaccine. Black patients were found more likely to develop them than white.
A study out of the University of Montreal explores newer, more accurate methods of targeting "HIV reservoirs" and tests two drugs, originally developed for cancer treatment, for their ability to bring the virus out of hiding.
The Penn Medicine clinical trial uses kidneys from deceased donors who were infected with the hepatitis C virus. The first person in the trial received a kidney transplant in July and then underwent treatment with a regimen of Zepatier, one of the direct acting antiviral drugs approved recently to treat the virus.
A retrospective cohort analysis showed patients with severe asthma and elevated eosinophil levels accounted for only 3% of all asthma patients but an estimated $1.3 billion in costs due to hospital admission for asthma exacerbation.